Lindner H, Willich H, Atzinger A
Institut für Strahlentherapie und Radiologische Onkologie, Klinikum Ingolstadt, West Germany.
Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1203-6. doi: 10.1016/0360-3016(90)90229-d.
Eighty-four patients with an ovarian carcinoma Stage I-III received an adjuvant whole abdominal irradiation (WAI) with pelvic boost postoperatively. Surgery included a bilateral salpingo-oophorectomy, hysterectomy, and omentectomy in 59% of the patients; in 41% surgery was less radical. For the whole abdominal irradiation we used the moving-strip method on 43 patients. The open-field technique was used on the other patients. Median dose of WAI was 22.5 Gy and median pelvic dose was 45.5 Gy. After a median follow-up of 68.5 months, a 5-year survival rate of 64 +/- 5.7% was determined, as well as a 5-year NED rate of 61.2 +/- 5.7%. Five-year survival rate was 80.1 +/- 7.4% in Stage I, 64.1 +/- 9.7% in Stage II, and 35.4 +/- 11.6% in Stage III. Five-year survival depended on tumor rest significantly. There was a trend to better prognosis when surgery was complete and grade was G1 or G2. The risk factor according to Dembo proved to be the most reliable prognostic factor: the 5-year survival rates were 75.0 +/- 6.3% for patients with intermediate risk and 20.1 +/- 10.4% for those with high risk (p = 0.001). Side effects were generally well tolerated. We only saw one serious complication, a radiation-induced small bowel obstruction.
84例I - III期卵巢癌患者术后接受了全腹照射(WAI)及盆腔加量照射。59%的患者手术包括双侧输卵管卵巢切除术、子宫切除术和大网膜切除术;41%的患者手术范围较小。43例患者在全腹照射时采用移动条野技术,其他患者采用开放野技术。WAI的中位剂量为22.5 Gy,盆腔中位剂量为45.5 Gy。中位随访68.5个月后,确定5年生存率为64±5.7%,5年无疾病证据(NED)率为61.2±5.7%。I期患者5年生存率为80.1±7.4%,II期为64.1±9.7%,III期为35.4±11.6%。5年生存率显著取决于肿瘤残留情况。手术完整且分级为G1或G2时,预后有改善趋势。根据Dembo标准,危险因素是最可靠的预后因素:中度风险患者5年生存率为75.0±6.3%,高风险患者为20.1±10.4%(p = 0.001)。副作用一般耐受性良好。我们仅观察到1例严重并发症,即放射性小肠梗阻。